References
- Miller A R, McBride W H, Hunt K K, Economou J S. Cytokine-mediated gene therapy. Ann Surg Oncol 1994; 1: 436–50
- Chiang C-S, Dougherty G J, Economou J S, McBride W H. Tumor-directed cytokine gene therapy. Gene therapy—from basic research to clinic, H Hui. World Scientific Pubishing Company Ltd., Singapore 1994; 20–44
- McBride W H, Dougherty G D, Wallis A E, Economou J S, Chiang C S. Interleukin-3 in gene therapy of cancer. Folia Biologica (Praha) 1994; 40: 62–78
- McBride W H, Thacker J D, Comora S, et al. Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity. Cancer Res 1992; 52: 3931–7
- Asher A L, Mule J J, Kasid, et al. Murine tumor cells transduced with the gene for tumor necrosis factor-α. Evidence for a paracrine immune effect of tumor necrosis factor against tumors. J Immunol 1991; 146: 3227–37
- Blankenstein T, Qin Z, Uberla K, et al. Tumor suppression after tumor cell-targeted tumor necrosis factor α gene transfer. J Exp Med 1991; 173: 1047–52
- Colombo M P, Modesti A, Parmiani G, Forni G. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res 1992; 52: 4853–7
- Hock H, Dorsch M, Diamanstein T, Blankenstein T. Interleukin 7 induces CD4+ T cell-dependent tumor rejection. J Exp Med 1991; 174: 1291–8
- Lavey R L, McBride W H, Comora S, . Effect of interleukin-6 on tumor cell growth in vivo and in vitro. IL-6: 6hysiopathology and clinical potentials, M Revel, et al. Raven Press, NY 1992; 273–80
- Pulaski B A, McAdam A J, Hunter E K, Biggar S, Lord E M, Frelinger J G. Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism. Cancer Res 1993; 53: 2112–7
- Russell S J, Eccles S A, Fleming C L, Johnson C A, Collins M LL. Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA. Int J Cancer 1991; 47: 244–51
- Dougherty G J, Thacker J D, Larey R S, Belldegrun A, McBride W H. Inhibitory effect of locally produced and exogenous interleukin-6 on tumor growth in vivo. Cancer Immunol Immunother 1994; 38: 339–45
- Hong J H, Gatti R A, Huo Y K, Chiang C-S, McBride W H. G2/M-phase arrest and release in ataxia telengiectasia and normal cells after exposure to ionizing radiation. Radiat Res 1994; 140: 17–23
- Dranoff G, Jafee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539–43
- Dubinett S M, Huang M, Dhanini S, et al. Interleukin 7 down-regulates murine fibrosarcoma transforming growth factor-β expression. 1995, (in press)
- Dubinett S M, Huang M, Dhanan S, Wang J, Berioza T. Downregulation of macrophage transforming growth factor-b messenger mRNA expression by IL-7. J Immunol 1993; 151: 6670–91
- McKenna W G, Iliakis G, Weiss M C, Bernhard E J, Muschel R J. Increased G2 delay in radiation-resistant cells obtained by transformation of primary rat embryo cells with onciogenes H-ras and v-myc. Radiat Res 1991; 125: 283–7
- Milas L, Wike J, Hunter N, Volpe J, Basic I. Macrophage content of murine sarcomas and carcinomas: associations with tumor growth parameters and radiocurability. Cancer Res 1987; 47: 1069–75